Predictive Oncology Inc Stock Price, News & Analysis

Predictive Oncology (NASDAQ: POAI) reported Q1 2022 revenue of $314,568, up from $280,317 in Q1 2021, driven by a 6% increase in the Skyline segment and initial sales from zPREDICTA. The company reduced its loss per share to $0.05 from $0.11 year-over-year. Cash and equivalents stood at $25 million with no long-term debt. While general and administrative expenses decreased to $2.4 million, operating expenses rose due to zPREDICTA's staffing. The gross profit margin remained steady at 65%. The firm is optimistic about its commercialization efforts for Helomics and zPREDICTA.

Predictive Oncology (NASDAQ: POAI) has appointed Theresa Ferguson as Senior Director of Marketing. This role is pivotal as the company moves toward commercializing its AI-driven technologies aimed at developing personalized cancer therapies. Ferguson's expertise in marketing and public relations will support and guide strategic initiatives to enhance the company's market presence and profitability. CEO J. Melville Engle emphasizes this appointment as a step towards achieving sales and marketing traction in core markets, reflecting the company’s commitment to business growth.

Predictive Oncology (POAI) reported its financial results for 2021, revealing revenue of $1.4 million, an increase from $1.25 million in 2020. The company strengthened its balance sheet with $55 million raised, and a significant acquisition of zPREDICTA, enhancing its drug discovery capabilities. However, it recorded a net loss of $19.7 million, down from $25.9 million in 2020, with accumulated deficits reaching $128 million. Operational expenses rose due to payroll and cloud computing costs, while goodwill impairment from previous acquisitions impacted financial metrics, emphasizing the need for sustainable growth.

Predictive Oncology (NASDAQ: POAI) has achieved a significant milestone with its PeDAL platform through the Discovery 21 campaign, which validated the platform's ability to make high-confidence predictions on ovarian tumor samples. The PeDAL platform demonstrated a drug response prediction accuracy of 91.8% across 175 FDA-approved drugs and 130 tumor samples. This breakthrough is expected to attract pharmaceutical partnerships and enhance drug discovery efficiency, aligning with the company’s mission of optimizing cancer therapies.

Predictive Oncology (NASDAQ: POAI) aims to lead in the AI drug discovery market, projected to reach $20 billion within three years. The company plans to market its PeDAL™ platform, having completed successful evaluations, which enhance treatment predictions for specific cancers. POAI anticipates establishing new partnerships and generating revenue from PeDAL-powered projects this year. The development costs for new oncology drugs exceed $35M, making efficient drug discovery crucial. With a database of over 150,000 tumors, POAI employs AI to optimize cancer treatments and improve patient outcomes.

Predictive Oncology Inc. (NASDAQ: POAI) announced preliminary results from its Discovery 2021 program, highlighting its AI-driven CoRE™ program's ability to identify potential new uses for chemotherapy drugs in ovarian cancer. The integration of Helomics' data with the PeDAL™ (Patient-centric Discovery by Active Learning) initiative allowed for predictions on drug efficacy across various cancers. PeDAL demonstrated confident predictions from a limited sample, potentially reducing drug development costs for partners. The company emphasizes its multiomic approach to personalized cancer therapies.

Predictive Oncology (Nasdaq: POAI) held its Annual Meeting of Stockholders on December 23, 2021, but it was adjourned due to insufficient quorum. Only 46% of the shares entitled to vote were represented. The meeting has been rescheduled for December 30, 2021, to allow more stockholders to participate. Stockholders of record as of October 26, 2021, are encouraged to vote before December 29, 2021. The company continues to solicit votes during this period. The proxy statement detailing voting proposals is available on the SEC website and the company's investor relations page.

Predictive Oncology (POAI) is enhancing its capabilities through the acquisition of zPREDICTA, a leader in cancer solutions, known for its patented 3D cell culture platform. This strategic move aims to expand POAI's reach in personalized cancer therapies, leveraging zPREDICTA's established revenue streams and client base in pharmaceutical sectors. The acquisition, alongside the hiring of Pamela Bush to lead sales efforts, supports POAI's transition from R&D to a revenue-generating biopharmaceutical company.

Predictive Oncology (POAI) has announced the appointment of Pamela Bush, Ph.D., MBA, as SVP of Strategic Sales and Business Development. With nearly 20 years of experience, Bush aims to commercialize the company's innovative cancer research technologies. CEO Mel Engle highlighted her role in optimizing treatment predictions for pharmaceutical and healthcare partners. Additionally, Bush will assist in business development and integrate the recently acquired zPREDICTA into the company's offerings.